CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 520 enrolled
Drug / intervention
e-cigarette +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02342795
NCT02342795Phase 2Completed
CompareCT.gov

Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation

Virginia Commonwealth University·interventional·Posted Jan 21, 2015·Updated Sep 7, 2018

In Brief

A Phase 2 clinical trial evaluating e-cigarette and cigarette substitute for Nontherapeutic. Completed, enrolled 520 participants across 2 sites.

Detailed Summary

The purpose of this study is to use Randomized Controlled Trial (RCT) methods to examine the influence of novel tobacco products on biomarkers of toxicant exposure and disease risk, reports of adverse events, and concurrent use of other tobacco products. In this case, the novel products are one type of electronic cigarette and an imitation cigarette or cigarette substitute.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNontherapeutic
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), Penn State University, Food and Drug Administration (FDA)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 21, 2015
Enrollment StartJun 1, 2015
Primary CompletionJun 1, 2018
Study CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.4 years ago

Interventions

e-cigaretteother

cigarette substituteother